Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635722 | 0.90 | LMNA (0.38) | TDP1TSHRKDM4EACLYKMT2A | |
| SCHEMBL2635965 | 0.87 | TDP1 (0.51) | TDP1TSHRKDM4EKMT2APTGDR2 | |
| SCHEMBL2635847 | 0.85 | GAA (0.42) | TDP1TSHRKDM4EPOLBMAPT | |
| SCHEMBL2635555 | 0.85 | MAPT (0.52) | TDP1KDM4EKMT2ACYP2C19POLB | |
| SCHEMBL2635997 | 0.84 | ACLY (0.44) | TDP1TSHRKDM4EACLYKMT2A | |
| SCHEMBL2636251 | 0.83 | RAB9A (0.56) | KDM4EKMT2ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL2636150 | 0.83 | SMN1; SMN2 (0.41) | TDP1TSHRKMT2ACYP2C19POLB | |
| SCHEMBL2635524 | 0.83 | NPC1 (0.49) | KDM4EKMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL2635691 | 0.82 | MAPT (0.47) | TDP1KDM4EKMT2ACYP2C19POLB | |
| SCHEMBL2636300 | 0.81 | ALDH1A1 (0.45) | TDP1TSHRKMT2ACYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | TDP1 2961/4885TSHR 3302/4885KDM4E 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.